The most common adverse effects for<unk>  in adults are upper respiratory infections, dizziness, and back pain. People with type 2 diabetes and kidney disease may experience diarrhea, fatigue, low blood pressure, low blood glucose, elevated potassium, chest pain, or allergic reaction.<unk>  should not be taken by people who are diabetic and taking aliskiren. Anemia may occur, due to inhibition of the renin–angiotensin system. As with other angiotensin receptor blockers,<unk>  may injure the liver, although this effect appears to be rare. Electrolyte imbalances may occur in people with kidney problems who take<unk> . Adverse outcomes do not differ by sex, age or race. Pregnancy In October 2014, the U.S. Food and Drug Administration (FDA) issued a black box warning that<unk>  can cause fetal toxicity, and should be discontinued as soon as pregnancy is detected. Using<unk>  while pregnant could result in fetal injury or death. Overdose Overdosing would most likely result in decreased blood pressure, which could manifest as an increased heart rate, dizziness, feeling light headed, or<unk> s of consciousness. Mice studies showed that lethality occurred at about 44 to 170 times the maximum recommended dose after the mice weights were taken into account. Interactions<unk>  may have adverse interactions with phenobarbital, rifampin, or fluconazole, possibly inhibiting its blood pressure-lowering effects. Contamination Between November 2018 and September 2019, the FDA announced multiple recalls of tablets containing<unk>  by Sandoz, Torrent Pharmaceuticals, Hetero Labs, Camber Pharmaceuticals, Legacy Pharmaceutical Packaging, Teva Pharmaceuticals, Vivimed Life Sciences, and Macleods Pharmaceutical Limited due to detection of one of the possible carcinogens N-nitrosodiethylamine, N-methylnitrosobutyric acid, or N-nitroso-N-methyl-4-aminobutyric acid in the active pharmaceutical ingredient (API).
Losartan
Olmesartan
Valsartan
Irbesartan
Azilsartan
Telmisartan
Cyclothiazide
Candesartan